65,437 trials
Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus
Primary: Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months) — 416; 417 Participants — p=<0.001
Fibrinogen Deficiency
Primary: Maximum Clot Firmness (MCF) — 0; 8.9 millimeters — p=<0.0001
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 — -2.38; -1.49 Percent — p=<0.001
Migraine, Without Aura
Primary: Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose. — 25; 64; 20; 54 Participants — p=<0.001
Haemophilus Influenzae Type B · Hepatitis B
Primary: The Number of Anti-HBs Seroprotected Participants 1 Month After the Third Dose. — 230; 226 Participants
Rotavirus Infections
Primary: Occurence of Clinical Rotavirus Disease Caused by the Composite of the Serotypes Contained Within the Vaccine More Than 14 Days Following the Third Dose. — 15; 54…
Blepharospasm
Primary: Change From Baseline to Week 4 in Blepharospasm Disability Index — -2.8; -1.3 Points on Scale
Puberty, Precocious
Primary: Change in Growth Rate (cm/Year) — -1.62 cm/year — p=0.278
Chronic Idiopathic Urticaria
Primary: Mean Pruritus Severity Score Over the First Week of Treatment — 1.02; 1.18 Units on a scale — p=<0.001
Peripheral Artery Disease
Primary: Major Adverse Events (MAEs) Within 30 Days — 2 Participants
Aortic Aneurysm, Abdominal
Primary: Time to First Major Adverse Event Experienced by Subjects From the Time of Treatment Through 1 Year — 84.0 days — p=0.003
Phenylketonurias
Primary: Amount of Dietary Supplemented Phenylalanine (Phe)Tolerated in Children With Phenylketonuria — 20.9; 2.9 mg/kg/day — p=<0.001
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) — 3291.411; 3439.867 ng per mL
Epilepsy
Primary: Percentage Change in Partial Seizure Frequency (All Partial Seizure Types) Between Baseline and the 12 Week Observation Period — -33.33 percentage change in events
Hepatitis B Virus Infection
Primary: The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 7 — 49; 64 Participants